Edition:
United States

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

8.73USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$8.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
74,138
52-wk High
$12.00
52-wk Low
$3.75

Latest Key Developments (Source: Significant Developments)

Aeglea Biotherapeutics Announces Proposed Public Offering
Tuesday, 17 Apr 2018 04:01pm EDT 

April 17 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 4.50 MILLION COMMON SHARES.  Full Article

Aeglea Biotherapeutics announces clinical collaboration with Merck
Monday, 16 Oct 2017 08:00am EDT 

Oct 16 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer.Aeglea Bio Therapeutics Inc - ‍collaboration agreement is between Aeglea Biotherapeutics and Merck, through a subsidiary​.Aeglea Bio Therapeutics Inc - ‍additional details of collaboration were not disclosed​.Aeglea Bio Therapeutics Inc - ‍enrollment to multicenter phase 1/2 study​ is expected to begin in Q1 of 2018.  Full Article

Aeglea Bio Therapeutics doses 2 patients in repeat dose as part of clinical trial
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Bio Therapeutics doses two patients in repeat dose part of phase 1/2 clinical trial for the treatment of arginase 1 deficiency.Aeglea Bio Therapeutics -‍dosed 2 adults in repeat dose part of phase 1/2 clinical trial of AEB1102 for treatment of patients with Arginase 1 Deficiency​.  Full Article

Aeglea BioTherapeutics reports Q2 loss per share $0.47‍​
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Aeglea BioTherapeutics Inc -:Aeglea BioTherapeutics provides corporate update and reports second quarter 2017 financial results.Q2 revenue $1.5 million versus I/B/E/S view $1.3 million.Aeglea BioTherapeutics - qtrly loss per share $0.47‍​.  Full Article

Aeglea Bio Therapeutics Inc's says CEO resigned
Thursday, 20 Jul 2017 04:01pm EDT 

July 20 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Bio Therapeutics Inc - ‍announced that David G. Lowe, PH.D., resigned as company's president, chief executive officer​.Aeglea Bio Therapeutics Inc - Anthony Quinn, M.B CH.B, PH.D., has been appointed to serve as interim chief executive officer​.Aeglea Bio Therapeutics Inc - conducting search for a permanent chief executive officer​.  Full Article

Aeglea Biotherapeutics says public offering of 3 mln shares priced at $4.10 per share
Tuesday, 6 Jun 2017 09:20am EDT 

June 6 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics prices public offering of common stock.Aeglea Bio Therapeutics - pricing of its underwritten public offering of 3 million shares of common stock at a public offering price of $4.10 per share.  Full Article

Aeglea Biotherapeutics announces proposed public offering of common stock
Monday, 5 Jun 2017 04:01pm EDT 

June 5 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics announces proposed public offering of common stock.‍Aeglea intends to use net proceeds from offering to fund research and development of its product candidates among others​.  Full Article

Aeglea Biotherapeutics Q1 revenue $1.0 mln vs $900,000
Tuesday, 9 May 2017 08:00am EDT 

May 9 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea biotherapeutics provides corporate update and reports first quarter 2017 financial results.Q1 revenue $1.0 million versus $900,000.Q1 revenue view $1.7 million -- Thomson Reuters I/B/E/S.Aeglea bio therapeutics inc - net loss totaled $6.2 million and $4.5 million for q1 of 2017 and 2016, respectively.Aeglea bio therapeutics inc - at march 31, 2017, aeglea had available cash, cash equivalents and marketable securities of $57.9 million.  Full Article

Aeglea Bio Therapeutics files for mixed shelf of up to $150 mln
Monday, 1 May 2017 04:00pm EDT 

May 1 (Reuters) - Aeglea Bio Therapeutics Inc :Files for mixed shelf of up to $150 million - SEC filing.  Full Article

Aeglea Bio Q4 revenue $1.2 million versus $1.6 million
Thursday, 23 Mar 2017 04:05pm EDT 

Aeglea Bio Therapeutics Inc : Aeglea biotherapeutics provides corporate update and reports fourth quarter and full year 2016 financial results . Q4 revenue $1.2 million versus $1.6 million . Q4 revenue view $3.4 million -- Thomson Reuters I/B/E/S . Aeglea bio therapeutics inc- believes that it has sufficient capital resources to fund anticipated operations through q1 of 2019 .Aeglea bio therapeutics inc- net loss totaled $5.5 million and $4.0 million for q4 of 2016 and 2015, respectively.  Full Article

BRIEF-Aeglea Biotherapeutics Announces Proposed Public Offering

* AEGLEA BIOTHERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK